✦ LIBER ✦

Part II: Management of resistance to imatinib in chronic myeloid leukaemia

✍ Scribed by Jane F Apperley

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Part I: Mechanisms of resistance to imat

✍ Jane F Apperley 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 421 KB

Resistance to imatinib mesylate in chron

✍ Junia V. Melo; Charles Chuah 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 416 KB

Metabolic characteristics of imatinib re

✍ Jelena Klawitter; Douglas J Kominsky; Jaimi L Brown; Jost Klawitter; Uwe Christi 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 614 KB

Evaluation of antileukaemic effects of r

✍ C. Sillaber; M. Mayerhofer; A. Böhm; A. Vales; A. Gruze; K. J. Aichberger; H. Es 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

Zoledronate inhibits proliferation and i

✍ Chuah, C; Barnes, D J; Kwok, M; Corbin, A; Deininger, M W N; Druker, B J; Melo, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 178 KB

Dasatinib is safe and effective in unsel

✍ Roberto Latagliata; Massimo Breccia; Fausto Castagnetti; Fabio Stagno; Luigiana 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 382 KB